Frankfurt - Delayed Quote EUR
Geron Corporation (GON.F)
1.0900
+0.0490
+(4.71%)
As of 3:31:52 PM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | 46.85M | 52.35M | 198.72M | 313.51M |
| Low Estimate | 42.02M | 47.47M | 182.78M | 266.39M |
| High Estimate | 50.85M | 55.4M | 208M | 357.4M |
| Year Ago Sales | 882k | 28.27M | 76.99M | 198.72M |
| Sales Growth (year/est) | 5,212.10% | 85.16% | 158.10% | 57.76% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| GON.F | -- | -- | -- | -- |
| S&P 500 | 13.17% | 2.85% | 7.92% | 13.78% |
Upgrades & Downgrades
| Downgrade | Scotiabank: Sector Outperform to Sector Perform | 5/8/2025 |
| Reiterates | Needham: Buy to Buy | 3/12/2025 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 3/12/2025 |
| Maintains | Scotiabank: Sector Outperform to Sector Outperform | 2/27/2025 |
| Maintains | Stifel: Buy to Buy | 2/27/2025 |
| Maintains | Barclays: Overweight to Overweight | 2/27/2025 |
Related Tickers
ABUS Arbutus Biopharma Corporation
3.0850
-1.12%
KPTI Karyopharm Therapeutics Inc.
5.31
-2.39%
DAWN Day One Biopharmaceuticals, Inc.
6.23
+1.14%
FGEN FibroGen, Inc.
0.3070
+1.66%
AXSM Axsome Therapeutics, Inc.
108.72
+1.39%
IOVA Iovance Biotherapeutics, Inc.
1.6550
-5.97%
SRPT Sarepta Therapeutics, Inc.
35.85
+1.64%
NVAX Novavax, Inc.
6.59
+4.77%